Bilypsa is a medicine that contains saroglitazar, a novel drug developed for managing metabolic disorders, especially in people with high cholesterol, type 2 diabetes, and fatty liver disease. It is commonly prescribed for patients who have a combination of elevated triglycerides and type 2 diabetes, or those suffering from non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Bilypsa offers a unique approach by targeting both lipid and glucose metabolism at the same time.

Mechanism of Action

Saroglitazar in Bilypsa works as a dual PPAR agonist, specifically activating PPAR alpha and PPAR gamma receptors. These receptors play key roles in regulating fat and sugar metabolism:

• PPAR alpha activation helps reduce triglyceride levels and improves fat metabolism in the liver.

• PPAR gamma activation improves insulin sensitivity and helps lower blood glucose levels.

  Uses

  Bilypsa is used for:

  • Management of high triglyceride levels in patients with type 2 diabetes

  • Treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

  • Helping control cholesterol and blood sugar in patients with mixed dyslipidemia

  • Reducing liver inflammation and fat accumulation in people at risk of liver complications

    Adverse Effects

    Bilypsa is generally well tolerated, but some individuals may experience mild side effects such as:

    • Gastric discomfort or bloating

    • Muscle or joint pain

    • Tiredness or dizziness

    • Weight gain in a few cases

    • Elevated liver enzymes, which may require regular monitoring

    • Mild swelling in the feet or ankles